The chromatin immunoprecipitation (ChIP) assay data showed that doxorubicin treatment promoted the binding of HP1γ to the promoter region of UBE2L3 gene in cervical cancer cells (Figure 5B–D). This evidence concerns the gene UBE2L3 and cervical carcinoma.